Ultratrutide
Also known as · Next-generation triple agonist
Overview
A newer multi-receptor incretin built on the retatrutide template, discussed for weight reduction with comparatively greater preservation of lean mass. Human trial data are not yet published in peer-reviewed form.
Research profile · for clinicians
Based on research: the newest entrant in the triple-agonist class. Interest centres on the ratio of fat-mass to lean-mass loss, an acknowledged limitation of earlier incretins.
Mechanism of action
Simultaneous agonism of GLP-1, GIP, and glucagon receptors — the incretin arms suppress intake and improve insulin sensitivity while glucagon-receptor activity raises energy expenditure.
Research record
- [01]Mechanistic rationale drawn from published retatrutide Phase 2 results.
- [02]No peer-reviewed human trial results published to date.
Selected references
Triple-hormone-receptor agonist retatrutide for obesity
N. Engl. J. Med., 2023
Research deep dive
Every cited study, explained
Plain-language walkthroughs of each reference, with direct PubMed links and dosing-literature context.